Results 31 to 40 of about 2,147 (178)
Interleukin-1β inhibitors for the management of acute gout flares: a systematic literature review
Arthritis Research & Therapy, 2023 Objectives The objective of this systematic review was to assess the effects of interleukin-1β (IL-1β) inhibitors on gout flares. Methods Studies published between 2011 and 2022 that evaluated the effects of IL-1β inhibitors in adult patients ...
Naomi Schlesinger +3 more
doaj +1 more source
Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now?
Frontiers in Pharmacology, 2021 Polygenic autoinflammatory diseases (AIDs), such as systemic juvenile idiopathic arthritis (sJIA), adult-onset Still's disease, Kawasaki disease, idiopathic recurrent pericarditis (IRP), Behçet’s Syndrome, Crystal-induced arthropatihes such as gout or ...
Hana Malcova +7 more
doaj +1 more source
Tuberculosis in children and adolescents with rheumatic diseases using biologic agents: an integrative review [PDF]
Revista Paulista de Pediatria, 2023 Objective: To conduct a bibliographic review on tuberculosis (TB) disease in children and adolescents with rheumatic diseases, being managed with biologic therapy. Data source: An integrative review with a search in the U.S. National Library of Medicine
Lenita de Melo Lima +5 more
doaj +1 more source
Pediatric Rheumatology Online Journal, 2020 Background Deficiency of the natural antagonist of interleukin-1 was first described in 2009 and so far 20 patients has been reported. In Brazil just two cases have been reported both carrying the same homozygous 15 bp deletion.
Leonardo Oliveira Mendonça +9 more
doaj +1 more source
Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis [PDF]
The Journal of Clinical Pharmacology, 2014 Systemic juvenile idiopathic arthritis (sJIA) is a disease characterized by arthritis in children
Julie Autmizguine +3 more
openaire +2 more sources
Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator [PDF]
, 2013 Introduction In phase-3 clinical trials, the interleukin (IL-1) blocker, rilonacept (IL-1 Trap), demonstrated efficacy for gout flare prevention during initiation of urate-lowering therapy.
Robert A Terkeltaub +15 more
core +1 more source
, 2022 Recurrent pericarditis affects 15-30% of patients after acute pericarditis. A large number of the patients with recurrent pericarditis can become corticosteroid dependent, leading to disease chronicity and drug dependence, with additional morbidity from ...
Gupta, Manasvi +6 more
core +1 more source
Aging Cell, Volume 25, Issue 9, September 2026.The aging of the human body is a complex process driven by multiple contributing factors. Based on their underlying mechanisms, current anti‐aging interventions can be classified into six primary categories. This paper summarizes the most promising anti‐aging strategies within each class. ABSTRACT The global prevalence of aging and age‐related diseases
Feifei Li +4 more
wiley +1 more source
Metabolic Regulation of Macrophages in Health and Disease
MedComm, Volume 7, Issue 8, August 2026.Extracellular metabolites drive metabolic rewiring of glucose, lipid, and amino acid pathways in macrophages, steering their polarization toward pro‐ or anti‐inflammatory phenotypes and shaping a wide range of disease processes. Macrophages from different tissues display distinct metabolic signatures, and therapeutic strategies that target these ...
Shan Huang +6 more
wiley +1 more source
Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and SARS-CoV-2 Vaccination: Results From the RHAPSODY Long-term Extension. [PDF]
BACKGROUND: Rilonacept inhibits the interleukin-1 pathway, and extended treatment in patients with recurrent pericarditis (RP) reduced recurrence risk by 98% in the phase 3 trial, RHAPSODY long-term extension (LTE).
Klutstein, Marc +16 more
core +3 more sources